|

Interview with Ian McCall

ByPsychedelic Spotlight

Similar Posts

  • MindMed Taking On The $30 BILLION Pain Relief Industry? [MMED / MNMD Expanding with Project Angie ]

    Listen, Videos

    Project Angie: Can MindMed Disrupt the Pain Relief Industry? [MMED / MNMD Expanding Horizons]
    Breaking NEWS: MindMed ( MNMD / MMED / MMQ ) launching a new flagship program called Angie to advance the development of psychedelics, including LSD and potentially penetrate the pain killer industry by treating pain conditions. MindMed is currently exploring two primary clinical indications for the treatment of pain:

    MindMed will initiate a study of LSD in a severe pain indication. MMED is currently preparing a pre-IND briefing package for this Phase 2a Proof of Concept study. They plan to submit to the FDA in the second half of 2021.
    ( As a note, that means they could present this doc anywhere between July 1st and December 31st. So it is conceivable that this trial could start at the tail end of 2021, if this doc gets presented at the beginning of that period.)
    The second indication that MindMed is evaluating is “the common, often debilitating, chronic pain syndrome”.

    Link to the 1964 study testing the LSDs ability to treat pain in cancer patients, and it had dual surprising results

    : file:///C:/Users/maria/Downloads/Study_of_Lysergic_Acid_Diethylamide_as_an.13.pdf
    Link to the 2020 a study was published that had among its authors 2 prominent MindMed collaborators: Mattias Liechti and Kim Kuypers: https://journals.sagepub.com/doi/full…​
    Link to the 2017study: https://www.ncbi.nlm.nih.gov/pmc/arti…​

    Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/​
    Link to MindMed ‘ s Press Release on Project Angie : https://mindmed.co/news/press-release…​

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifa…​
    https://benzinga.grsm.io/thepsychedel…​

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed​ #MindMedStock​ #MNMD

  • Interview with Zoe Helene, Founder of Cosmic Sister

    Listen, Podcasts

    In our conversation, we discuss some of Zoe’s formative experiences in the creative arts which led her down the path of plant medicine advocacy, core feminist issues and how psychedelics play a role in furthering women’s movements, why an emphasis on equity and representation within the budding psychedelic industry is crucial and still has a long way to go, and so much more.

  • Interview With Dr. Gorman

    Listen, Podcasts

    In this episode of the Psychedelic Spotlight podcast, we speak with Dr. Ingmar Gorman who is the Co-Founder and Lead Trainer at Fluence, and a Principal Investigator for the Multidisciplinary Association for Psychedelic Studies (“MAPS”).ya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.